Lingshu Wang

TL;DR: An engineering strategy for stabilization of soluble S proteins in the prefusion conformation is described, which results in greatly increased expression, conformational homogeneity, and elicitation of potent antibody responses, and an engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV.

TL;DR: A mouse vaccination model is described that allows a germline human IGHV1-2(∗)02 segment to undergo normal V(D)J recombination and leads to the generation of peripheral B cells that express a highly diverse repertoire of VRC01-related receptors.

TL;DR: The LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset as mentioned in this paper.

TL;DR: Overcoming host restriction of two Middle East respiratory syndrome (MERS)-like bat CoVs using exogenous protease treatment demonstrates that proteolytic cleavage is the primary barrier to infection for a subset of zoonotic coronaviruses.

TL;DR: It is shown that m336, an exceptionally potent human anti-MERS-CoV antibody, is almost germline with only one somatic mutation in the heavy chain, revealing that its IGHV1-69-derived heavy chain provides more than 85% binding surface and that its epitope almost completely overlaps with the receptor-binding site.